Life Sciences Tools Industry Background

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Life Sciences Tools Industry Background"

Transcription

1 Life Sciences Tools Industry Background October 2003 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of Forward-looking statements may be identified by words such as "expects", "anticipates","intends", "plans", "believes", "seeks", "estimates", "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of GE resulting from and following the Acquisition. These statements are based on management's current expectations and are inherently subject to uncertainties and changes in circumstances. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are factors relating to satisfaction of the Pre-Conditions and the Conditions, GE s ability to successfully combine the businesses of GE Medical Systems and Amersham and to realize expected operating synergies from the Acquisition, and changes in global, political, economic, business, competitive, market and regulatory forces. More detailed information about certain of these factors is contained in GE s and Amersham s filings with the SEC. Neither GE nor Amersham undertakes any obligation to update the forward-looking statements to reflect actual results, or any change in events, conditions, assumptions or other factors. The foregoing does not constitute an offer for sale of any securities or an offer or an invitation to purchase any such securities. If and when GE commences its proposed acquisition of Amersham and the acquisition is implemented by way of a scheme of arrangement, any securities to be issued pursuant to the scheme of arrangement will not be registered under the Securities Act but will be issued in reliance on the exemption provided by Section 3(a)(10) thereof, and Amersham will furnish the acquisition document to the SEC under cover of a Form 6-K. If and when GE commences its proposed acquisition of Amersham and the acquisition is implemented by way of an offer rather than a scheme of arrangement, GE will file a registration statement relating to the offer with the SEC. If GE files a registration statement with the SEC, it will contain a prospectus and other documents relating to the offer. Such prospectus and other documents will contain important information about GE, Amersham, the offer and related matters. Holders of Amersham securities who are U.S. persons or who are located in the United States are urged to read such prospectus (if any) and other documents that would form part of such registration statement if and when it becomes available before they make any decision with respect to the offer. Holders of Amersham securities should also read the related solicitation/recommendation statement on Schedule 14D-9 that will be filed with the SEC by Amersham relating to the offer. Such prospectus and any other relevant documents filed by GE and Amersham with the SEC will be available free of charge at the SEC s web site at and from GE. These documents will also be available for inspection and copying at the public reference room maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C , US. For further information about the public reference room, call the SEC at The directors of GE accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of GE (who have taken all reasonable care to ensure that such is the case), the information contained in this presentation for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information. The contents of this presentation are not intended to mean that General Electric earnings or earnings per share for any period will necessarily exceed those of any prior year. 2

2 Amersham Biosciences Overview Life Science Tools Overview Industry Dynamics and Challenges Key Segments Key Players Drug Discovery and Process Key Technologies Key Amersham Offerings 3 4

3 Enabling Molecular Medicine Instruments and for Drug Discovery and Excellent Product Offering Discovery Systems High Value-add Delivers High Margins in 30+% OP Instruments and Flow Business 26,000 Unit Installed Base (Lab + Production) Customers Research Labs, Biotechs, Pharmaceuticals, Government Competitors Waters, Applied Bio, Agilent, Perkin Elmer, Invitrogen, Millipore, and others Sales ($B) Financial Summary Industry Size: ~$15B Industry Growth: 5-10% 8% CAGR $0.9 $ E OP% 10% 11% (LTM 1H FY 2003) 14% CAGR Separation Discovery Systems Exciting 5 New Platform Great Business Today & Strategic Homerun Amersham Participates in All Phases of Process Discovery & Research & ~$25B Global Pharma Spend +11% CAGR 400+ New Investigational Drug Filings Annually Drug Process & Clinical Trials ~$40B Spend on & Clinical Trials +12% CAGR 2,300 Total Clinical Trials Based Trials Commercial & 30 New Drugs Approved Annually Capacity Growing 50% per Year Amersham Sales to Pharmaceutical Customer Base 35% Systems 65% ($B) Discovery Systems 2003E Revenue $0.6B Discovery & Research & Clinicals Commercial & $0.5B New Channel Opportunity for GE Imaging Equipment 6 Entry Into Largest Segment In Healthcare Drug

4 Demand for Amersham Offerings Driven by Rapid Growth of Life Sciences & Bio-Pharma # in Bio-pharmaceuticals in Nov-99 May-00 Nov-00 May-01 Nov-01 May-02 Nov-02 Drug Process Discovery & Research & Clinicals Key Amersham Technologies & DNA Analysis - Understand Basis of Disease Why? Analysis - Understand Disease Function How? Bio-Assays Screen Potential Drugs for Impact on Living Cells. Analyze Drug Candidates for Toxicology, i.e. Safety Discovery Systems Sequencing, Genotyping, Expression Analysis, Analysis, Screening Bioprocess sales ( m) No of approved biopharmaceuticals Commercial &Manuf g Production Scale-Up & Large-Scale Biopharma Lab and Production e 2004e 2005e 2006e 40 0 Researchers and Bio-pharma Companies Need Large Quantities of Pure s for Drug R&D and More for Production 7 Well-Positioned with Lots of Ways To Grow Life Science Tools Overview 8

5 Instruments and for Analytical Studies $26B Industry Industrial Tools Life Science Tools Industrial Applications Petrochemical Environmental Testing Agricultural / Food $11B $15B Biological Studies Pharmaceuticals/ Biotech Drug Discovery & Source: SDI and GE estimates Provide Enabling Technologies for Drug a nd Molecular Medicine 9 Life Sciences Tools: Enabling Molecular and Personalized Medicine Life Science Tools Industry Dynamics Instruments and for Use in the Drug Discovery, & Process Industry Growth Rates 98 03E 9% CAGR $15B Instruments 54% Segments 46% Instruments $7.1 $6.4 $9B $5.7 $4.9 $4.2 $3.6 $5.5 $6.2 $6.8 $7.3 $7.8 $8.3 Customers E Source: Deutsche Bank, SDI and GE estimates Government / Academia 40% Biotechnology 20% Pharmaceutical 40% Historic Drivers: Current Drivers:, Sequencing efforts NIH Funding Sequencing / Drug Homeland Defense Funding Growth Shifted from -Based to -Based Tools 10

6 Key Challenges in Drug Discovery and New Challenges Historical Bottlenecks Focused in the Target Discovery Phase Historically the Global Pharmaceutical Industry was built on few targets With the advent of the post-human genome era, number of targets discovered has exploded Current challenges for pharmaceutical companies include: Validating new targets Reducing the drug development time Faster prediction of drug failure Rescue of drugs with utility for patients with certain genetic makeup Instruments and Help Biotech and Pharma Overcome New Challenges 11 Major Life Sciences Players Top Life Science Companies by 2002 Revenue ($B) * Applied Bio $1.7 Thermo Electron $1.2 Amersham $1.0 Shimadzu $1.0 Perkin Elmer $1.0 Waters $0.9 Millipore $0.7 Invitrogen $0.6 Becton Dickinson $0.6 Mettler Toledo $0.6 Beckman Coulter $0.6 Agilent $0.5 Varian $0.5 Bio-Rad $0.4 Affymetrix $0.3 Sigma Aldrich $0.3 Qiagen $0.3 Source: Annual Reports, Analyst Research * Revenues from Life Sciences Only 12 Selected Players by Segment Affymetrix, Agilent, Amersham, Applied Bio, Invitrogen, Orchid, Perkin Elmer, Qiagen, Sequenom Agilent, Amersham, Applied Bio, Becton Dickinson, Bio-Rad, Bruker, Invitrogen, Qiagen, Thermo, Waters Amersham, Becton Dickinson, Beckman Coulter, Perkin Elmer, Tecan Amersham, Bio-Rad, Millipore, Waters, others Molecular Spectroscopy Bruker, Perkin Elmer, Shimadzu, Thermo, Varian General Lab Equipment Agilent, Beckman Coulter, Mettler Toledo, Shimadzu, Thermo, Waters Applied Bio, Amersham, Becton Dickinson, Bio-Rad, Invitrogen, Perbio, Qiagen, Sigma Aldrich, Techne

7 Life Science Customers Life Science Customer Segments Pharmaceutical 40% Government / Academia 40% Top Pharmaceutical Companies by R&D Spending Driven by NIH Funding 2002 R&D Spending ($B) Pfizer GSK AstraZeneca Aventis Roche NIH Funding ($B) J&J Novartis Merck BMS Eli Lilly Wyeth Source: SEC Reports E Source: Deutsche Bank Biotechnology 20% Top Biotech Companies by R&D Spending 2002 R&D Spending ($B) Amgen Genentech Millenium Biogen Chiron Genzyme Source: SEC Reports 13 Life Sciences Tools Two Categories of Life Sciences Tools Instrumentation And Instrumentation High End Equipment for Advanced Scientific Discovery: - Mass Spectrometry - DNA Microarrays - Microarrays - DNA Sequencers - High Throughput Screening - Productivity Instruments Used for Routine Analysis: - High Performance Liquid Chromatography Instruments 54% Revenue by Segment 2003E 46% Life Sciences and Consumables Consumables Utilized in R&D And Drug Molecular Biology: - Cloning and DNA/RNA Manipulation - s & Immunoassays - Electhrophores to Separate, Analyze & Isolate DNA, RNA and s - Cell Cultures: - Tissue Culture Media - Animal Sera - Growth/Attachment Factors : - Expression and Functional Studies Instruments $8B Segment CAGR: 4-8% $7B Segment CAGR: 7-13% 14

8 The Process... The Process to Create New Drugs Target Discovery Target Validation Lead Discovery Lead optimization Pre-Clinical and Clinical Studies Biopharmaceutical The Key Segments... Size $3.0B AAGR 9-12% Sequencing Gene Expression SNP Analysis Size $2.5B AAGR 10-15% Analysis and Identification Size $2.0B AAGR 9-12% Drug Screening Toxicology Size $1.5B AAGR 10-15% Purification Biopharmaceutical manufacturing Bioinformatics /Laboratory Information Management Systems Size $2.0B AAGR 6-9% Molecular Spectroscopy Size $1.0B AAGR 3-5% General Laboratory Equipment Size $3.0B AAGR 3-5% Source: Deutsche Bank, SDI and GE estimates Amersham Offerings 15 Key Technologies Enabling Drug Discovery and Definition Study of Genes Study of s Experiments to identify potential drugs suitable to enter human clinical trials Process used for the manufacturing of Biopharmaceuticals Business Drivers Sequencing of organisms to understand gene function Analysis of genetic variation Need to understand gene function in terms of protein activity -protein interactions Pharmaceutical companies need to increase productivity in drug discovery to meet revenue growth targets Growing number of approved Biopharmaceuticals and Biopharmaceuticals in Clinical Trials DNA Sequencing Gel Electrophoresis High Throughput Liquid Screening Key Chromatography DNA Microarrays Mass Spectroscopy Technologies 16 Amersham Offerings

9 Key Amersham Offerings 17 Key Amersham Offerings Target Discovery Target Validation Lead Discovery Lead optimization Pre-Clinical and Clinical Studies Biopharmaceutical Sequencing MegaBACE tm TempliPhi tm Genephor tm Gene Expression CodeLink tm Lucidea tm CyeDye tm SNP Analysis CodeLink tm Analysis and Identification ETTAN tm 2D DIGE Typhoon tm Drug Screening LEADseeker tm Cytostar-T tm Biotrak tm Toxicology IN Cell Analyzer tm Custom Labels Purification & Scale-up AKTA tm Biopharmaceutical manufacturing Sepharose TM Chromaflow tm Source tm Laboratory Information Management System: Scierra tm Source: Amersham 18

10 Key Technologies Enabling Drug Discovery and DNA Sequencing DNA Sequencers are used in first step of drug discovery to determine the sequence of nucleotides in a given sample of DNA Systems that break apart a sample of DNA, tag each of its nucleotides with a different color and uses a laser beam to cause the tagged nucleotides to fluoresce. The colors are optically scanned and a sequence of nucleotides is established After, the completion of the Human Genome Project has has shifted to studies of companion genomes. Amersham Offers MegaBACE TM, a Fluorescence-based DNA Analysis System MegaBACE TM 19 DNA Sequencers Demand Has Shifted from Human Genome Project Key Technologies Enabling Drug Discovery and DNA Microarrays DNA Microarrays are Glass wafers coded with complementary sequences of Genes. DNA Probes bind to their complements in a given biological sample through a technique known as hybridization Amersham Offers CodeLink TM, DNA Microarrays for Gene Expression and SNP Analysis Used primarily in Gene Expression and Genotyping studies for Target Identification and Target Validation Can be also used for Toxicology Studies, during clinical trials to stratify patient groups, and for diagnosis and Prognosis Have the potential to be used for Pharmacogenomics CodeLink TM 20

11 Gel Electrophoresis is Technology used to performed Expression analysis. Key Technologies Enabling Drug Discovery and Gel Electrophoresis s are separated on a gel by their charge and size, and appear as spots on the gel. The gel is then digested with an enzyme and the proteins are isolated for further analysis using an instruments such as a Mass Spectrometers Gel Electrophoresis systems can offer one- and two-dimensional separation, with the latter providing more detailed analysis as proteins are separated horizontally and vertically across the gel Amersham Offers Ettan TM and 2D DIGE TM, Integrated Systems for Expression Analysis Ettan TM 21 Core Technology to Perform Expression Analysis Key Technologies Enabling Drug Discovery and Mass Spectrometers are used to identify and quantify analytes through measuring the molecule mass to charge ratio A sample is converted into positively or negatively charged particles that then proceeds into a mass analyzer, where using a magnetic field the particles are separated based on mass Useful technology for quantification of compounds and for determining chemical and structural information Premier methodology for characterization Mass Spectrometry Amersham Offers Ettan TM MALDI- TOF, an Integrated Platform for Analysis and Identification Amersham Also Has a Strategic Alliance With Thermo in This Segment Ettan TM MALDI-TOF 22 Mass Spectrometry Is Leading Technology for Studies

12 Key Technologies Enabling Drug Discovery and High Throughput Screening High Throughput Screening technology includes the use of liquid handling and sample preparation products and detection systems to screen hundreds of thousands of compounds for biological activity against a test assay, to identify potential drug candidates. Demand is driven by the products of the Human Genome Project, which has yielded a multitude of targets against which to screen compounds. Amersham Offers LEADseeker TM, a Multi-Modality System for Screening Assays Using Fluorescent, Chemiluminescent and Radioactive Chemistries LEADseeker TM High Throughput Screening Driven by Products of the Human Genome Project 23 Key Technologies Enabling Drug Discovery and Liquid Chromatography Liquid Chromatography systems are used to separate bio-molecules according to their hydrophobic/ hydrophilic properties A solution containing the biomolecule to be isolated together with a number of other contaminants is poured down a column packed with resins. The target bio-molecules and some contaminants bind to these resins and are detached in turn when buffers are passed down the column Amersham Offers AKTA TM, a Chromatography Platform for Product Purification and Separation AKTA TM 24 Liquid Chromatography Is A Key Technology for BioPharma

13 Key Technologies Enabling Drug Discovery and are biological and chemical materials consumed by scientists performing experiments to uncover the sequence and function on genes Three Types of : Molecular Biology: Used for the studies of genes and proteins Cell Culture: Used in both Research and Bioproduction Chromatography Consumables: Used for separation, identification and characterization of s 65% of Amersham Biosciences Revenue Derived from and Consumables Amersham Systems Based : MegaBACE TM : DNA Sequencing / Genotyping Ettan TM 2D DIGE: Expression Analysis Amersham Stand-Alone : ECL Advance: Analysis TempliPhi TM : DNA sample preparation CyDye: Fluorescent Labelling 25 Represent Majority of Amersham s BioSciences Business Spotlight on Key Technology for Manufacture Biopharmaceuticals Biopharmaceuticals, or protein-based drugs, represent the most attractive classes of therapeutic compounds in the market generating over $24B in revenue in 2002, an increase of 34% over 2001 with more than 400 drugs in development 26 Fermenter Cell Harvesting Capture Virus Clearance Ultrafiltration Removal Polishing Source: UBS Warburg Purification Process Instruments & Centrifugation and/or filtration Chromatography: Capture target protein, wash away majority of contaminants Chemical/heat/filtration Removing any particles by filtration Adsorption of contaminants by chromatography Final chromatography step to remove contaminants very similar to the product Isolation and Purification of s on Small Scale (Laboratory) and Large Scale (Bioprocess) Most Commonly Used Techniques Are Chromatography & Cross-Flow Filtration Needed for Production Active Drug Substances in a Highly Pure Form and in High Yields Very Strict FDA Regulation for the of Biopharmaceuticals FDA Focus on Identity, Purity and Potency FDA Requires Bio-Equivalence to be Demonstrated Between Clinical Trial Process and Commercialized Products Critical for Suppliers To Get Into Drug Process Early Enables Production of Pure -Based Drugs at High Yields

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES MAY 2014. May 2014 ABA 298 1 Technologies, Products & Services

More information

TECHNOLOGY PATENTS IN THE (CONTINUED)... 16

TECHNOLOGY PATENTS IN THE (CONTINUED)... 16 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 INTENDED AUDIENCE... 2 ANALYST CREDENTIALS...

More information

Chapter 20: Biotechnology

Chapter 20: Biotechnology Name Period The AP Biology exam has reached into this chapter for essay questions on a regular basis over the past 15 years. Student responses show that biotechnology is a difficult topic. This chapter

More information

Microarray Technology

Microarray Technology Microarrays And Functional Genomics CPSC265 Matt Hudson Microarray Technology Relatively young technology Usually used like a Northern blot can determine the amount of mrna for a particular gene Except

More information

Cell Discovery 360: Explore more possibilities.

Cell Discovery 360: Explore more possibilities. Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle

More information

POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS

POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS BIO087C August 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-333-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Common Course Topics Biology 1414: Introduction to Biotechnology I

Common Course Topics Biology 1414: Introduction to Biotechnology I Common Course Topics Biology 1414: Introduction to Biotechnology I Assumptions Students may be enrolled in this course for several reasons; they are enrolled in the Biotechnology Program, they need a science

More information

STANDARD 2 Students will demonstrate appropriate safety procedures and equipment use in the laboratory.

STANDARD 2 Students will demonstrate appropriate safety procedures and equipment use in the laboratory. BIOTECHNOLOGY Levels: 11-12 Units of Credit: 1.0 CIP Code: 51.1201 Prerequisite: Biology or Chemistry Skill Certificates: #708 COURSE DESCRIPTION is an exploratory course designed to create an awareness

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

NUVISAN Pharma Services

NUVISAN Pharma Services NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!

More information

Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources

Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources 1 of 8 11/7/2004 11:00 AM National Center for Biotechnology Information About NCBI NCBI at a Glance A Science Primer Human Genome Resources Model Organisms Guide Outreach and Education Databases and Tools

More information

Next Generation Sequencing Informatics Markets

Next Generation Sequencing Informatics Markets Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development

Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development Protein Quantification workshop, Waters: 13 th November 2012 Vincent Monchois, R&D and Pilot Services Manager,

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

SOLUTIONS FOR NEXT-GENERATION SEQUENCING

SOLUTIONS FOR NEXT-GENERATION SEQUENCING SOLUTIONS FOR NEXT-GENERATION SEQUENCING GENOMICS CELL BIOLOGY PROTEOMICS AUTOMATION enabling next-generation research From Samples To Publication, Millennium Science Enables Your Next-Gen Sequencing Workflow

More information

Total Test Questions: 71 Levels: Grades 10-12 Units of Credit: 1.0 STANDARD 1 STUDENTS WILL INVESTIGATE THE PAST, PRESENT, AND FUTURE APPLICATIONS OF

Total Test Questions: 71 Levels: Grades 10-12 Units of Credit: 1.0 STANDARD 1 STUDENTS WILL INVESTIGATE THE PAST, PRESENT, AND FUTURE APPLICATIONS OF DESCRIPTION Biotechnology is designed to create an awareness of career possibilities in the field of biotechnology. Students are introduced to diagnostic and therapeutic laboratory procedures that support

More information

Chapter 20: Biotechnology: DNA Technology & Genomics

Chapter 20: Biotechnology: DNA Technology & Genomics Biotechnology Chapter 20: Biotechnology: DNA Technology & Genomics The BIG Questions How can we use our knowledge of DNA to: o Diagnose disease or defect? o Cure disease or defect? o Change/improve organisms?

More information

Student Portfolios. Introduction:

Student Portfolios. Introduction: Student Portfolios Introduction: The purpose of the student portfolio is three fold. 1] From your perspective it will provide a resource that you can review when it comes time to apply for Grad School,

More information

INDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services

INDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services The information and statistics set out in this section and other sections of this document were extracted from different official government publications, available sources from public market research

More information

Introduction to Proteomics 1.0

Introduction to Proteomics 1.0 Introduction to Proteomics 1.0 CMSP Workshop Tim Griffin Associate Professor, BMBB Faculty Director, CMSP Objectives Why are we here? For participants: Learn basics of MS-based proteomics Learn what s

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

From The Lab To Your Medicine Cabinet:

From The Lab To Your Medicine Cabinet: From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Lab 1: Who s Your Daddy? (AKA DNA Purification and PCR)

Lab 1: Who s Your Daddy? (AKA DNA Purification and PCR) Lab 1: Who s Your Daddy? (AKA DNA Purification and PCR) Goals of the lab: 1. To understand how DNA s chemical properties can be exploited for purification 2. To learn practical applications of DNA purification

More information

Creating a Stronger, More Efficient Competitor Able to Meet Growing Challenges of a Rapidly Changing Industry. February 20, 2013

Creating a Stronger, More Efficient Competitor Able to Meet Growing Challenges of a Rapidly Changing Industry. February 20, 2013 Creating a Stronger, More Efficient Competitor Able to Meet Growing Challenges of a Rapidly Changing Industry February 20, 2013 Discussion of Forward-Looking Statements OFFICE DEPOT SAFE HARBOR STATEMENT

More information

Department of Biology Sample

Department of Biology Sample Syllabus BIOTECHNOLOGY Spring 2013 Instructor: Atanu Duttaroy, Professor Tel: 202-806-5362 Email: aduttaroy@howard.edu Office: Room 336, Just Hall Teaching Assistant: Mr. Subhas Mukherjee Lecture: Room

More information

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands ETHICS AND THE PSM Bioethics Education in Professional Science Master s Programs at California State University Channel Islands Ching-Hua Wang, M.D., Ph.D., Director of MS Biotechnology and Bioinformatics

More information

Recombinant DNA Technology

Recombinant DNA Technology PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University C H A P T E R 8 Recombinant DNA Technology The Role of Recombinant DNA Technology in Biotechnology Biotechnology

More information

Using Molecular Markers in Plant Genetics Research Unlocking genetic potential for increased productivity

Using Molecular Markers in Plant Genetics Research Unlocking genetic potential for increased productivity Using Molecular Markers in Plant enetics Research Unlocking genetic potential for increased productivity Molecular Markers Researchers at Pioneer blaze a new genetic trail. Identifying molecular markers

More information

Chapter 8: Recombinant DNA 2002 by W. H. Freeman and Company Chapter 8: Recombinant DNA 2002 by W. H. Freeman and Company

Chapter 8: Recombinant DNA 2002 by W. H. Freeman and Company Chapter 8: Recombinant DNA 2002 by W. H. Freeman and Company Biotechnology and reporter genes Here, a lentivirus is used to carry foreign DNA into chickens. A reporter gene (GFP)indicates that foreign DNA has been successfully transferred. Recombinant DNA continued

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

BIOMEDICAL SCIENCE: A COURSE THAT COUNTS

BIOMEDICAL SCIENCE: A COURSE THAT COUNTS BIOMEDICAL SCIENCE: A COURSE THAT COUNTS Department of Pharmacy, Health and Well-being Why study Biomedical at Sunderland? By studying Biomedical at Sunderland, you are choosing to put your future career

More information

Aim #29: NYS Biodiversity Lab Review

Aim #29: NYS Biodiversity Lab Review Name: Aim #29: NYS Biodiversity Lab Review Date: 1. Which chemicals are used to cut DNA into fragments for a gel electrophoresis procedure? A) enzymes B) molecular bases C) hormones D) ATP molecules 2.

More information

Biomedical sensors in the pharmaceutical industry Olav Flaten

Biomedical sensors in the pharmaceutical industry Olav Flaten Biomedical sensors in the pharmaceutical industry Olav Flaten MD PhD FFPM Medical Director GlaxoSmithKline Health Care Industry Pharmaceutical Industry/Big Pharma: Fine pharmaceuticals: Innovative drugs;

More information

BIOSCIENCES COURSE TITLE AWARD

BIOSCIENCES COURSE TITLE AWARD COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,

More information

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS 1. The Technology Strategy sets out six areas where technological developments are required to push the frontiers of knowledge

More information

TOP TEN SUPPLIERS OF FOOD SAFETY PRODUCTS AND TECHNOLOGY. FOD053A February Vijay Subramanian Project Analyst ISBN: X

TOP TEN SUPPLIERS OF FOOD SAFETY PRODUCTS AND TECHNOLOGY. FOD053A February Vijay Subramanian Project Analyst ISBN: X TOP TEN SUPPLIERS OF FOOD SAFETY PRODUCTS AND TECHNOLOGY FOD053A February 2013 Vijay Subramanian Project Analyst ISBN: 0-89336-925-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,

More information

Transcript of Arrayit Corporation Third Quarter 2014 Earnings Conference Call November 26, 2014

Transcript of Arrayit Corporation Third Quarter 2014 Earnings Conference Call November 26, 2014 Transcript of Arrayit Corporation Third Quarter 2014 Earnings Conference Call November 26, 2014 Participants Rene Schena Chairman, Chief Executive Officer Presentation Operator Greetings and welcome to

More information

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri)

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,

More information

Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies

Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies, MBS Molly Schmid, Ph.D. Table of Contents Introduction.2 Methodology.. 2 Results

More information

Name Class Date. KEY CONCEPT Mutations are changes in DNA that may or may not affect phenotype. frameshift mutation

Name Class Date. KEY CONCEPT Mutations are changes in DNA that may or may not affect phenotype. frameshift mutation Unit 7 Study Guide Section 8.7: Mutations KEY CONCEPT Mutations are changes in DNA that may or may not affect phenotype. VOCABULARY mutation point mutation frameshift mutation mutagen MAIN IDEA: Some mutations

More information

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd. Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided

More information

Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update

Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

Selling into Life Science Research 2020 The ecommerce shift

Selling into Life Science Research 2020 The ecommerce shift www.pwc.com Selling into Life Science Research 2020 The ecommerce shift Dr. Nikolas Beutin Dr. David Pumberger Agenda Page 1 Today s Life Science Research Market 1 2 The ecommerce shift 5 3 Way forward

More information

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April 2013 1 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics

More information

HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter)

HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Chapter 20: Biotechnology

Chapter 20: Biotechnology Name Period Chapter 20: Biotechnology The AP Biology exam has reached into this chapter for essay questions on a regular basis over the past 15 years. Student responses show that biotechnology is a difficult

More information

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,

More information

Repligen Reports Third Quarter 2015 Financial Results

Repligen Reports Third Quarter 2015 Financial Results Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference

More information

This report is supported by members of United for Medical Research and a supplemental UMR contribution from Life Technologies.

This report is supported by members of United for Medical Research and a supplemental UMR contribution from Life Technologies. About United for Medical Research United for Medical Research represents leading research institutions, patient and health advocates and private industry, joined together to seek steady increases in federal

More information

General Electric Company Financial Services Funding Policy

General Electric Company Financial Services Funding Policy General Electric Company Financial Services Funding Policy "This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking

More information

Biotechnology Engineering

Biotechnology Engineering Biotechnology Engineering What it means to be a Biotechnology Engineer! Gajendra Circle Initiative (GCI) from IIT Madras Alumni Association and The Hindu Group May 15, 2010 Compiled by: Adayana Learning

More information

Recombinant DNA and Biotechnology

Recombinant DNA and Biotechnology Recombinant DNA and Biotechnology Chapter 18 Lecture Objectives What Is Recombinant DNA? How Are New Genes Inserted into Cells? What Sources of DNA Are Used in Cloning? What Other Tools Are Used to Study

More information

Joseph Wagner, Ph.D. Chief Executive Officer OncoCyte Corporation

Joseph Wagner, Ph.D. Chief Executive Officer OncoCyte Corporation Joseph Wagner, Ph.D. Chief Executive Officer OncoCyte Corporation Forward Looking Statements The matters discussed in this presentation include forward looking statements which are subject to various risks,

More information

GE 2014 third quarter performance

GE 2014 third quarter performance GE 2014 third quarter performance Financial results & Company highlights October 17, 2014 Forward-Looking Statements: This document contains forward-looking statements that is, statements related to future,

More information

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases

More information

Biotechpharma company profile

Biotechpharma company profile Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing

More information

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in

More information

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014 The Stock Market Show Parsortix non-invasive cancer diagnostics Andrew Newland 13 September 2014 Legal disclaimer The information and opinions contained in this presentation are provided as at the date

More information

CRIME LAB FORENSICS. Course Overview

CRIME LAB FORENSICS. Course Overview CRIME LAB FORENSICS Description Crime Lab Forensics, which is a laboratory-based course, will promote and cultivate the development of student s scientific inquiry and scientific method skills, which are

More information

COVANCE INC. NYSE: CVD

COVANCE INC. NYSE: CVD COVANCE INC. NYSE: CVD JOE HERRING CHAIRMAN AND CEO June 3, 2014 Safe Harbor Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings,

More information

Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)

Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus) STRATEGY FOCUS Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus) A strategic sales model for BI solutions in Big Pharma and Biotech Reference Code: BFTC1675

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

Synthetic Biology Market. Future Market Insights. Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016

Synthetic Biology Market. Future Market Insights. Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016 Synthetic Biology Market Share, Global Trends, Analysis,, Report, Opportunities, Segmentation and Forecast, 2016 Future Market Insights www.futuremarketinsights.com sales@futuremarketinsights.com Future

More information

Recombinant Paper Plasmids Cut-and-Paste Biotechnology

Recombinant Paper Plasmids Cut-and-Paste Biotechnology Recombinant Paper Plasmids Cut-and-Paste Biotechnology OBJECTIVE / RIONALE Bioengineers make news using recombinant DNA techniques in hopes of curing genetic diseases, better understanding cancer, and

More information

Genetics Faculty of Agriculture and Veterinary Medicine

Genetics Faculty of Agriculture and Veterinary Medicine Genetics 10201232 Faculty of Agriculture and Veterinary Medicine Instructor: Dr. Jihad Abdallah Topic 15:Recombinant DNA Technology 1 Recombinant DNA Technology Recombinant DNA Technology is the use of

More information

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012!

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012! Avacta Group plc Innovation for global health Interim Results 25th April 2012 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company

More information

12/6/12. Dr. Sanjeeva Srivastava. IIT Bombay 2. Genomics Transcriptomics Why proteomics? Proteomics Course NPTEL

12/6/12. Dr. Sanjeeva Srivastava. IIT Bombay 2. Genomics Transcriptomics Why proteomics? Proteomics Course NPTEL Dr. Sanjeeva Srivastava IIT Bombay Genomics Transcriptomics Why proteomics? IIT Bombay 2 1 IIT Bombay 3 Genome: The entire sequence of an organism s hereditary information, including both coding and non-coding

More information

QIAGEN Management Buyout Synthetic DNA Business Unit Conference Call

QIAGEN Management Buyout Synthetic DNA Business Unit Conference Call QIAGEN Management Buyout Synthetic DNA Business Unit Conference Call July 1, 2004 Welcome to QIAGEN s Conference Call Second Management Quarter Buyout and Synthetic Half Year DNA 2003 Business Conference

More information

GFP Transformation Genetic Manipulations

GFP Transformation Genetic Manipulations MODULE 2 Objective 2.1 Lesson E GFP Transformation Genetic Manipulations Course Advanced Biotechnology Unit DNA Technology Essential Question How is foreign DNA genes taken up by organisms and expressed?

More information

An Introduction to Genomics and SAS Scientific Discovery Solutions

An Introduction to Genomics and SAS Scientific Discovery Solutions An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!

More information

Big Data Healthcare. Fei Wang Associate Professor Department of Computer Science and Engineering School of Engineering University of Connecticut

Big Data Healthcare. Fei Wang Associate Professor Department of Computer Science and Engineering School of Engineering University of Connecticut Big Data Healthcare Fei Wang Associate Professor Department of Computer Science and Engineering School of Engineering University of Connecticut Healthcare Is in Crisis Hersh, W., Jacko, J. A., Greenes,

More information

Setting the Standard for Plasmid DNA Production

Setting the Standard for Plasmid DNA Production Setting the Standard for Plasmid DNA Production Dr. Wolfgang Buchinger Boehringer Ingelheim RCV GmbH & Co. KG Contact: bioxcellence@boehringer-ingelheim.com Gene Vaccination and Gene Therapy Nucleic acid

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

Chapter 10 Manipulating Genes

Chapter 10 Manipulating Genes How DNA Molecules Are Analyzed Chapter 10 Manipulating Genes Until the development of recombinant DNA techniques, crucial clues for understanding how cell works remained lock in the genome. Important advances

More information

Profile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,

More information

Using Genomics in Plant Genetics Research

Using Genomics in Plant Genetics Research Using Genomics in Plant Genetics Research Unlocking Genetic Potential for Increased Productivity Index 6 Bioinfomatics 2 Cell 3 Chromosome 6 Contig 3 DNA 6 DNA Chips 4 Expressed Sequence Tag (EST) 3 Gene

More information

Article 53(c) EPC - therapy

Article 53(c) EPC - therapy Article 53(c) EPC - therapy Compound X is not new, but no medical use (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) compound X for use as a medicament compound X for use in treating disease Y composition

More information

David Owen Licensing & IP business models. 27th of May, Paris

David Owen Licensing & IP business models. 27th of May, Paris David Owen Licensing & IP business models 27th of May, Paris LICENSING STRATEGY The key decision factors? Exclusive / non-exclusive? THESIS TTOs could and should make greater use of non-exclusive licensing

More information

Montgomery County Community College BIT 123 Techniques and Instrumentation for Biotechnology 4-3-3

Montgomery County Community College BIT 123 Techniques and Instrumentation for Biotechnology 4-3-3 Montgomery County Community College BIT 123 Techniques and Instrumentation for Biotechnology 4-3-3 COURSE DESCRIPTION: This course will allow students to gain theoretical and practical, hands-on knowledge

More information

Career Opportunities in the Life Sciences

Career Opportunities in the Life Sciences Career Opportunities in Biotechnology and Drug Career Opportunities in the Life Sciences Toby Beth Freedman, Ph.D. February 28 th, 2008 1 The Experiment A comprehensive, systematic assessment of careers

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

Biological Technicians

Biological Technicians SOC 19-4021: Assist biological and medical scientists in laboratories. Set up, operate, and maintain laboratory instruments and equipment, monitor experiments, make observations, and calculate and record

More information

In vitro Device Regulation

In vitro Device Regulation In vitro Device Regulation Molecular Pathologists Reagent (Analyte) Manufacturers High Complexity Clinical Labs Commercial Academic in Vitro Diagnostics Manufacturers Drug Developers large & small 2 States

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Biotechnology: DNA Technology & Genomics

Biotechnology: DNA Technology & Genomics Chapter 20. Biotechnology: DNA Technology & Genomics 2003-2004 The BIG Questions How can we use our knowledge of DNA to: diagnose disease or defect? cure disease or defect? change/improve organisms? What

More information

DEPARTMENT OF SCIENCE & TECHNOLOGY CHANDIGARH ADMINISTRATION

DEPARTMENT OF SCIENCE & TECHNOLOGY CHANDIGARH ADMINISTRATION BIO Technology Policy: DEPARTMENT OF SCIENCE & TECHNOLOGY CHANDIGARH ADMINISTRATION INTRODUCTION: Biotechnology is defined as the controlled use of biological agents, i.e. micro organisms or cellular components,

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Common Course Topics Biology 1406: Cell and Molecular Biology

Common Course Topics Biology 1406: Cell and Molecular Biology Common Course Topics Biology 1406: Cell and Molecular Biology 1. Introduction to biology --the scientific study of organisms --properties of life --assumptions, methods and limitations of science --underlying

More information

Title: Protein Isolation and Identification in Genetically Modified Food

Title: Protein Isolation and Identification in Genetically Modified Food Title: Protein Isolation and Identification in Genetically Modified Food Paula Ladd WestShore JR/SR HS This biotechnology unit is directed toward upper level science research students or AP Biology students.

More information

Biotechnology Sector Report

Biotechnology Sector Report Biotechnology Sector Report Technology Roadmap Project For the Prepared by: The information contained in this document is not warranted or guaranteed in any way and is provided "as is." Rensselaer does

More information